Neoadjuvant nivolumab (Opdivo) plus ipilimumab (Yervoy) followed by therapeutic lymph node dissection (TLND) and response-driven adjuvant therapy reduced the risk of progression, recurrence, or death by 68% compared with TLND and adjuvant nivolumab alone for patients with macroscopic stage III node-positive melanoma, according to findings from the phase 3 NADINA study presented at the 2024 ASCO Annual Meeting and simultaneously published in the New England Journal of Medicine.
Clinical Trials
Nivolumab Combo Improves EFS in Stage III Melanoma
Phase 3 findings show the benefit of immunotherapy before surgery in those with macroscopic stage III node-positive melanoma.
In Stage III Melanoma, Immunotherapy Combo Before Surgery Leads to Improved Survival, Less Therapy
The idea that patients could get better responses with shorter courses of therapy runs counter to the current standard of care in melanoma.
Pembrolizumab/Vibostolimab Coformulation for Melanoma to be Discontinued
The phase 3 KeyVibe-010 study will discontinue the coformulation of pembrolizumab and vibostolimab treatment for high-risk melanoma due to futility.